Precision Wealth Strategies LLC Makes New $530,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Precision Wealth Strategies LLC acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 17,608 shares of the biopharmaceutical company's stock, valued at approximately $530,000.

A number of other hedge funds have also made changes to their positions in TGTX. The Manufacturers Life Insurance Company increased its holdings in shares of TG Therapeutics by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 80,664 shares of the biopharmaceutical company's stock valued at $1,435,000 after acquiring an additional 2,871 shares during the last quarter. Creative Planning grew its stake in TG Therapeutics by 34.7% during the 2nd quarter. Creative Planning now owns 46,839 shares of the biopharmaceutical company's stock worth $833,000 after buying an additional 12,076 shares during the last quarter. SG Americas Securities LLC lifted its position in TG Therapeutics by 181.9% during the 3rd quarter. SG Americas Securities LLC now owns 23,614 shares of the biopharmaceutical company's stock worth $552,000 after acquiring an additional 15,238 shares during the period. Handelsbanken Fonder AB grew its holdings in TG Therapeutics by 22.6% during the third quarter. Handelsbanken Fonder AB now owns 49,900 shares of the biopharmaceutical company's stock worth $1,167,000 after acquiring an additional 9,200 shares during the period. Finally, Daymark Wealth Partners LLC increased its holdings in TG Therapeutics by 73.7% in the third quarter. Daymark Wealth Partners LLC now owns 40,811 shares of the biopharmaceutical company's stock valued at $955,000 after buying an additional 17,311 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on TGTX shares. TD Cowen initiated coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. StockNews.com cut shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. Finally, The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Up 1.1 %

Shares of TGTX stock traded up $0.37 during trading hours on Wednesday, hitting $33.28. 761,240 shares of the company were exchanged, compared to its average volume of 2,494,490. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business's 50-day simple moving average is $31.54 and its two-hundred day simple moving average is $26.74. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84. The stock has a market capitalization of $5.18 billion, a price-to-earnings ratio of -332.83 and a beta of 2.26.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics's revenue was down 49.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.73 EPS. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,358 shares of company stock worth $781,497. 10.50% of the stock is owned by insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.